Dr. Powles on Durvalumab in Urothelial Cancer

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.